IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats

Author(s):  Eichstadt Lauren R, Corriveau Lorraine A, Moore George E, Knipp Gregory T, Cooper Bruce R, Gwin Wilson E

Issue:  May/Jun 2017 - Volume 21, Number 3
View All Articles in Issue

Abstract:  The objective of this study was to compare serum concentrations of transdermal fluoxetine compounded in Lipoderm base versus commercially available oral fluoxetine tablets. Sixteen clinically healthy, client-owned cats that were at least one year of age were enrolled. Cats weighed between three and seven kilograms, had no comorbidities, and were behavior medication naïve. Cats were recruited from January 2016 through April 2016. Eight cats were assigned to each medication group based on owner preference. The cats received either oral (1 mg/kg) or transdermal (5 mg/kg; maximum 25 mg daily) fluoxetine compounded in a transdermal base (PCCA Lipoderm), administered daily for 60 days. Serum levels of fluoxetine and norfluoxetine were assessed as a surrogate for relative efficacy. Serum was collected and analyzed by high-performance liquid chromatography-mass spectrometry/mass spectrometry at baseline and days 5, 10, 30, 45, and 60 post-drug start. Adverse effects were monitored during physical exams, speaking with owners, and laboratory analysis of liver function tests at baseline and days 5, 30, and 60 post-drug start. Serum fluoxetine concentrations significantly differed between the treatment groups at days 45 and 60 post-drug start. Norfluoxetine concentrations significantly differed at days 30, 45, and 60 post-drug start. Blood concentrations of fluoxetine and norfluoxetine significantly differed between oral and transdermal routes after 30 days of treatment. Oral fluoxetine concentrations were consistently higher. Transdermal fluoxetine appeared to be well-tolerated, but a lack of knowledge regarding effective blood levels makes it unclear if a clinical effective response would be obtained at the blood concentrations achieved.

Related Keywords: Lauren R. Eichstadt, PharmD, Lorraine A. Corriveau, DVM, George E. Moore, DVM, PhD, Gregory T. Knipp, PhD, Bruce R. Cooper, PhD, Wilson E. Gwin, RPh, fluoxetine, selective serotonin reuptake inhibitor, SSRI, felines, anxiety, behavioral disorders, obsessive compulsive disorder, OCD, topical preparation, transdermal administration, transdermal absorption, serum drug concentrations, oral preparation, dosage form comparison

Related Categories: PEER-REVIEWED, VETERINARY, DOSAGE FORMS/DRUG CARRIERS

Printer-Friendly Version




Download in electronic PDF format for $35

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats Eichstadt Lauren R, Corriveau Lorraine A, Moore George E, Knipp Gregory T, Cooper Bruce R, Gwin Wilson E May/Jun 2017 242-246 Buy
Case Report: Transdermal Fluoxetine as Therapy for Feline Anxiety Fields Shannon W Nov/Dec 2006 418 Buy
Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh Allen Loyd V Jr Nov/Dec 2003 449-450 Buy
Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4 Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C Jul/Aug 2020 327-336 Buy
Fluoxetine 50 mg/mL in Pluronic Lecithin Organogel Allen Loyd V Jr Sep/Oct 2018 409 Buy
Compounding Transdermal Medication for Feline Patients Eichstadt Lauren R Jul/Aug 2016 271-274 Buy
Evaluation of the Stability of Fluoxetine in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date Peacock Gina F, Sauvageot Jurgita May/Jun 2014 253-255 Buy
Fluoxetine Hydrochloride 1-mg/mL Oral Liquid Allen Loyd V Jr Jan/Feb 2007 73 Buy
Feline Transdermal Formulation Considerations Forsythe Lauren Eichstadt Nov/Dec 2017 446-452 Buy
Feline Ophthalmic Disease: Feline Herpesvirus and Systemic Hypertension Davidson Michael G Mar/Apr 2001 92-94 Buy